Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

This study is for adults aged 18 or over. To join, you must have already taken part in an earlier study involving lorundrostat for high blood pressure and met all the requirements to move into this new phase. You'll need to sign a consent form to show you understand and agree to take part.

If you're a woman who could become pregnant, or a man whose partner could become pregnant, you'll need to agree to use reliable contraception during the study and for a short time afterwards. You also need to be able to follow the study instructions and attend all your scheduled appointments.

You cannot join this study if you are pregnant, planning to become pregnant, or breastfeeding. You also can't take part if you're using certain other medications that would interfere with the study, or if the study doctor believes there's any reason you shouldn't participate. There are also specific rules for joining the optional temporary treatment withdrawal part of the study, including consistently taking your medicine during the first 12 weeks.

If you decide to take part, the study will last about 52 weeks, which is roughly a year. After this, there will be a two-week period where the research team will check on your safety one last time. You'll attend regular visits to the clinic where you'll have check-ups, and the research team will assess your health and response to the medicine.

During this time, you will be taking the study medicine, lorundrostat. You'll receive clear instructions on how to take it. There's also an optional extra period, which you can choose to join after the main year, where you might continue taking the medicine until it's approved for general use or until the study finishes. Some participants might also be asked to take part in an optional, temporary withdrawal from the medicine to see how their body reacts.